Skip to main content
. 2021 May 10;22(9):5052. doi: 10.3390/ijms22095052

Figure 8.

Figure 8

Cassiabrevone inhibits gp120/CD4 interaction. (A) Hela-P4-CXCR4 cells pretreated with CE, guibourtinidol-(4α→8)-epiafzelechin), and cassiabrevone were incubated with hela-ENV-Lai cells. β-Galactosidase activity was accessed. Data were normalized to control cells without any drugs to give the percentage of fusion. (B) Cassiabrevone and guibourtinidol-(4α→8)- -epiafzelechin were tested in an in-house ELISA assay against gp120 binding activity. Data were normalized to control cells without compound treatment. ANOVA analysis was performed for statistical significance. * p < 0.05.